文献速递白血病

生理水平IGFBP7延长急性淋巴细胞白血病中IGF1R的激活

Physiologic IGFBP7 levels prolong IGF1R activation in acute lymphoblastic leukemia.
PubMed 文献 · Blood Adv · 2021-01-01

该研究探讨IGFBP7在急性淋巴细胞白血病(ALL)中的作用。体外和体内实验表明,IGFBP7通过延长IGF1R在细胞表面的滞留,增强胰岛素/IGF信号,对ALL细胞发挥促增殖和促存活的自分泌效应;敲低或中和IGFBP7可减弱白血病进展,提示其可作为抗体治疗靶点。

要点

  • IGFBP7对ALL细胞有促增殖和促存活的自分泌效应,依赖胰岛素/IGF信号。
  • IGFBP7敲低或抗体中和可降低ALL细胞活力并减缓白血病进展。
  • IGFBP7延长IGF1R表面滞留,持续激活IGF1R/IRS-1/AKT/ERK通路。

核心结论

  • IGFBP7通过促进IGF1R在细胞表面的持续存在,延长胰岛素/IGF刺激,在ALL中发挥致癌作用。
  • 临床前数据表明IGFBP7是ALL抗体治疗干预的有效靶点。

研究设计与样本

  • 研究采用体外ALL细胞实验和体内白血病进展模型,评估IGFBP7敲低或抗体中和的效果。

主要发现

  • IGFBP7敲低或抗体介导的中和显著减弱体外ALL细胞活力并抑制体内白血病进展。
  • IGFBP7延长胰岛素/IGF1刺激下IGF1R的表面滞留,导致IGF1R、IRS-1、AKT和ERK磷酸化持续。
  • 胰岛素刺激下胰岛素受体迅速内化并去磷酸化, despite IGFBP7存在。
  • IGFBP7存在时,25 ng/mL胰岛素导致的IGF1R激活水平与5 ng/mL IGF1等效。

关键数值与推荐

  • 同源二聚体IGF1R对胰岛素的亲和力比对IGF1低>100倍(据报告)。
  • IGFBP7存在时,25 ng/mL胰岛素引起IGF1R激活,等效于5 ng/mL IGF1。

临床怎么用

  • IGFBP7可作为ALL抗体靶向治疗的候选靶点,需进一步临床前和临床验证。

局限性

  • 研究为临床前数据,需在人体中验证IGFBP7靶向治疗的安全性和有效性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Insulin and insulin-like growth factors (IGFs) are mitogenic and prosurvival factors to many different cell types, including acute lymphoblastic leukemia (ALL). Circulating IGFs are bound by IGF binding proteins (IGFBPs) that regulate their action. IGFBP7 is an IGFBP-related protein (IGFBP-rP) that in contrast to other IGFBPs/IGFBP-rPs features higher affinity for insulin than IGFs and was shown to bind the IGF1 receptor (IGF1R) as well. The role of IGFBP7 in cancer is controversial: on some tumors, it functions as an oncogene, whereas in others, it functions as a tumor suppressor. In childhood ALL, higher IGFBP7 expression levels were associated with worse prognosis. Here we show that IGFBP7 exerts mitogenic and prosurvival autocrine effects on ALL cells that were dependent on insulin/IGF. IGFBP7 knockdown or antibody-mediated neutralization resulted in significant attenuation of ALL cell viability in vitro and leukemia progression in vivo. IGFBP7 was shown to prolong the surface retention of the IGF1R under insulin/IGF1 stimulation, resulting in sustained IGF1R, insulin receptor substrate 1 (IRS-1), protein kinase B (AKT), and extracellular signal-regulated kinase (ERK) phosphorylation. Conversely, the insulin receptor was readily internalized and dephosphorylated on insulin stimulation, despite IGFBP7 addition. The affinity of homodimeric IGF1R for insulin is reportedly >100 times lower than for IGF1. In the presence of IGFBP7, however, 25 ng/mL insulin resulted in IGF1R activation levels equivalent to that of 5 ng/mL IGF1. In conclusion, IGFBP7 plays an oncogenic role in ALL by promoting the perdurance of IGF1R at the cell surface, prolonging insulin/IGF stimulation. Preclinical data demonstrate that IGFBP7 is a valid target for antibody-based therapeutic interventions in ALL.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Artico LL, Laranjeira ABA, Campos LW, et al. Physiologic IGFBP7 levels prolong IGF1R activation in acute lymphoblastic leukemia. Blood Adv. 2021. PMID: 34438446. doi:10.1182/bloodadvances.2020003627

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。